Monopar Therapeutics (MNPR) PT Raised to $128 at Barclays
Tweet
Share
E-mailGet Alerts MNPR Hot Sheet
Price: $95.72 -0.78%
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
Barclays analyst Etzer Darout raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $128.00 (from $125.00) while maintaining a Overweight rating.
You May Also Be Interested In
- RBC Capital Downgrades LVMH (MC:FP) (LVMUY) to Sector Perform
- EssilorLuxottica SA (EL:FP) (ESLOY) PT Lowered to EUR190 at RBC Capital
- Hermes International (RMS:FP) (HESAY) PT Lowered to EUR1,600 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
